Resumen de acción ZYDUSLIFE
Zydus Lifesciences Limited se dedica a la investigación, desarrollo, producción, comercialización, distribución y venta de productos farmacéuticos en India, Estados Unidos y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Recompensas
Análisis de riesgos
Competidores de Zydus Lifesciences Limited
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | ₹963.10 |
| 52 Week High | ₹1,031.70 |
| 52 Week Low | ₹484.95 |
| Beta | 0.55 |
| 1 Month Change | -4.39% |
| 3 Month Change | 27.41% |
| 1 Year Change | 85.25% |
| 3 Year Change | 65.82% |
| 5 Year Change | 213.25% |
| Change since IPO | 11,000.00% |
Noticias y actualizaciones recientes
Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18
Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Recent updates
Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors
Dec 06With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case
Aug 23Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
Jul 17We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jun 24Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00
Jun 10Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
May 21Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Nov 13Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Shares Could Be 23% Below Their Intrinsic Value Estimate
Aug 09Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 25Zydus Lifesciences (NSE:ZYDUSLIFE) Has Announced That Its Dividend Will Be Reduced To ₹2.50
Jul 10Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Jul 07Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jun 23Zydus Lifesciences (NSE:ZYDUSLIFE) Is Reducing Its Dividend To ₹2.50
Jun 09Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Reduced To ₹2.50
May 26Rentabilidad de los accionistas
| ZYDUSLIFE | IN Pharmaceuticals | Mercado IN | |
|---|---|---|---|
| 7D | 0.4% | 2.0% | 2.4% |
| 1Y | 85.2% | 56.7% | 45.0% |
Rentabilidad vs. Industria: ZYDUSLIFE superó al sector Indian Pharmaceuticals , que obtuvo un rendimiento del 56.7% el año pasado.
Rentabilidad vs. Mercado: ZYDUSLIFE superó al mercado Indian, que obtuvo un rendimiento del 46.4% el año pasado.
Volatilidad de los precios
| ZYDUSLIFE volatility | |
|---|---|
| ZYDUSLIFE Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.2% |
Precio estable de las acciones: El precio de las acciones de ZYDUSLIFE ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ZYDUSLIFE (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1952 | 23,026 | Sharvil Patel | www.zyduslife.com |
Zydus Lifesciences Limited se dedica a la investigación, desarrollo, producción, comercialización, distribución y venta de productos farmacéuticos en India, Estados Unidos e internacionalmente. Opera a través de los segmentos de productos farmacéuticos y de consumo. Ofrece formulaciones humanas de dosificación acabada que comprenden genéricos, genéricos de marca y formulaciones especiales, incluidos biosimilares y vacunas; ingredientes farmacéuticos activos; productos de bienestar para el consumidor; y productos en las áreas terapéuticas de tratamiento del dolor, neurología, trastornos metabólicos y enfermedades hepáticas.
Resumen de fundamentos de Zydus Lifesciences Limited
| Estadísticas fundamentales de ZYDUSLIFE | |
|---|---|
| Capitalización bursátil | ₹953.31b |
| Beneficios(TTM) | ₹29.56b |
| Ingresos (TTM) | ₹190.24b |
32.8x
Ratio precio-beneficio (PE)5.1x
Ratio precio-ventas (PS)¿Está ZYDUSLIFE sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ZYDUSLIFE | |
|---|---|
| Ingresos | ₹190.24b |
| Coste de los ingresos | ₹64.73b |
| Beneficio bruto | ₹125.51b |
| Otros gastos | ₹95.95b |
| Beneficios | ₹29.56b |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
May 30, 2024
| Beneficios por acción (BPA) | 29.38 |
| Margen bruto | 65.97% |
| Margen de beneficio neto | 15.54% |
| Ratio deuda/patrimonio | 0.9% |
¿Cómo se ha desempeñado ZYDUSLIFE a largo plazo?
Ver rendimiento histórico y comparativa